Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epitestosterone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | SHBG | P04278 | 5/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 1.00 |
| ▸ | PGR | P06401 | 3/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 3/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | SNCA | P37840 | 2/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 2/20 | 1.00 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 1.00 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.73 |
| ▸ | ESR1 | P03372 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epitestosterone SCHEMBL14034478 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL617693 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Testosterone SCHEMBL145157 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL16305625 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL13752937 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL11588466 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL2678780 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL21957465 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL22704809 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL17808819 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912731-B2 | Use of silylated formiates as hydrosilane equivalents | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2024-02-27 | — | — | US | disclosed |
| US-20210292345-A1 | Use of Silylated Formiates as Hydrosilane Equivalents | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2021-09-23 | — | — | US | disclosed |
| US-10940205-B2 | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | THEMIS MEDICARE LIMITED (IN) | 2021-03-09 | — | — | US | disclosed |
| EP-2935572-B1 | ENGINEERED BIOCATALYSTS AND METHODS FOR SYNTHESIZING CHIRAL AMINES | CODEXIS INC (US) | 2020-09-30 | — | — | EP | disclosed |
| US-20180071390-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | THEMIS MEDICARE LIMITED (IN) | 2018-03-15 | — | — | US | disclosed |
| US-9827315-B2 | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | THEMIS MEDICARE LIMITED (IN) | 2017-11-28 | — | — | US | disclosed |
| US-20170239313-A1 | COMPOSITIONS AND METHODS COMPRISING EXTRACTS OF ZINGIBERACEAE | BIOCOGENT, LLC | 2017-08-24 | — | — | US | disclosed |
| US-20170239313-A1 | COMPOSITIONS AND METHODS COMPRISING EXTRACTS OF ZINGIBERACEAE | BIOCOGENT, LLC | 2017-08-24 | — | — | US | disclosed |
| EP-2449128-B1 | Enzymatic process for the preparation of testosterone using a \"tag\ | F I S - FABBRICA ITALIANA SINTETICI S P A (IT) | 2017-05-10 | — | — | EP | disclosed |
| EP-2093285-B1 | Method for biocatalysis using filamentous fungi | UNIV THE WEST INDIES (JM) | 2016-07-06 | — | — | EP | disclosed |
| US-20110207172-A1 | PROCESS FOR THE PREPARATION OF TESTOSTERONE | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2011-08-25 | — | — | US | disclosed |
| US-20110207172-A1 | PROCESS FOR THE PREPARATION OF TESTOSTERONE | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2011-08-25 | — | — | US | disclosed |
| WO-2011000693-A1 | PROCESS FOR THE PREPARATION OF TESTOSTERONE | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2011-01-06 | — | — | WO | disclosed |
| EP-2093285-A1 | Method for biocatalysis using filamentous fungi | The University of the West Indies (JM) | 2009-08-26 | — | — | EP | disclosed |
| US-20080063607-A1 | Oleaginous pharmaceutical and cosmetic foam | FOAMIX LTD | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292345-A1 | Use of Silylated Formiates as Hydrosilane Equivalents | PFAS, EPM2A, CYP2F1 | AR 3526/4885LMNA 400/4885CYP3A4 68/4885 |
| US-20180071390-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | DSG1, DEGS1, PLA2G2E | AR 719/4885LMNA 1490/4885CYP3A4 385/4885 |
| US-10940205-B2 | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | DSG1, DEGS1, PLA2G2E | AR 719/4885LMNA 1490/4885CYP3A4 385/4885 |
| US-11912731-B2 | Use of silylated formiates as hydrosilane equivalents | PFAS, EPM2A, CYP2F1 | AR 3526/4885LMNA 400/4885CYP3A4 68/4885 |
| US-20170239313-A1 | COMPOSITIONS AND METHODS COMPRISING EXTRACTS OF ZINGIBERACEAE | CYP17A1, CYP11A1, CUTA | AR 9/4885LMNA 1098/4885CYP3A4 1192/4885 |
| US-20080063607-A1 | Oleaginous pharmaceutical and cosmetic foam | LIPA, LIPC, PLIN3 | AR 1197/4885LMNA 2105/4885CYP3A4 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.